Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Dr. Laurent  Fischer

President, Chief Executive Officer & Director

Dr. Romuald  Corbau Ph.D.

Chief Scientific Officer

Dr. Setareh  Seyedkazemi Pharm.D.

Chief Development Officer

Dr. R. Andrew Ramelmeier Ph.D.

Chief Technology Officer

Ms. Dena  House

Chief People Officer

Mr. John W. Rakow J.D.

Senior Vice President & General Counsel

Ms. Carla  Fiankan

Senior Vice President of Regulatory Affairs

Mr. Kishor Peter Soparkar J.D.

Chief Operating Officer

Ms. Linda M. Rubinstein M.A.

Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer

Mr. Michael  Steel

Senior Vice President of Quality

Biotechnologie

Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. Management-Struktur

Informationen zum Management